{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:52:52Z","timestamp":1790466772058,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clbc.2020.06.011","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T02:27:56Z","timestamp":1593656876000},"page":"e63-e73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":172,"title":["The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3317-9804","authenticated-orcid":false,"given":"Stephanie L.","family":"Goff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7873-2063","authenticated-orcid":false,"given":"David N.","family":"Danforth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2020.06.011_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10549-014-2896-8","article-title":"Immune cell quantitation in normal breast tissue lobules with and without lobulitis","volume":"144","author":"Degnim","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.06.011_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1158\/1940-6207.CAPR-15-0370-T","article-title":"Analysis of immune cells from human mammary ductal epithelial organoids reveals Vdelta2+ T cells that efficiently target breast carcinoma cells in the presence of bisphosphonate","volume":"9","author":"Zumwalde","year":"2016","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.clbc.2020.06.011_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","article-title":"Single-cell map of diverse immune phenotypes in the breast tumor microenvironment","volume":"174","author":"Azizi","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.clbc.2020.06.011_bib5","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1136\/jcp.2005.031252","article-title":"Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations","volume":"59","author":"Hussein","year":"2006","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clbc.2020.06.011_bib6","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1073\/pnas.1104303108","article-title":"Leukocyte composition of human breast cancer","volume":"109","author":"Ruffell","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2020.06.011_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib8","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib9","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clbc.2020.06.011_bib12","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3892\/or.2015.4523","article-title":"Overexpressed genes associated with hormones in terminal ductal lobular units identified by global transcriptome analysis: an insight into the anatomic origin of breast cancer","volume":"35","author":"Yang","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clbc.2020.06.011_bib13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF00709984","article-title":"Intraepithelial lymphocytes and macrophages in the normal breast","volume":"407","author":"Ferguson","year":"1985","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"10.1016\/j.clbc.2020.06.011_bib14","first-page":"415","article-title":"Mononuclear cells in malignant and benign human breast tissue","volume":"107","author":"Giorno","year":"1983","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clbc.2020.06.011_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.2910360404","article-title":"An immunohistological study of leukocyte localization in benign and malignant breast tissue","volume":"36","author":"Lwin","year":"1985","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2020.06.011_bib16","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1158\/1078-0432.CCR-16-2026","article-title":"Alterations in the immune cell composition in premalignant breast tissue that precede breast cancer development","volume":"23","author":"Degnim","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2020.06.011_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000086659","article-title":"gammadelta T cells link innate and adaptive immune responses","volume":"86","author":"Holtmeier","year":"2005","journal-title":"Chem Immunol Allergy"},{"key":"10.1016\/j.clbc.2020.06.011_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1615\/CritRevImmunol.v23.i56.10","article-title":"Features and functions of gamma delta T lymphocytes: focus on chemokines and their receptors","volume":"23","author":"Kabelitz","year":"2003","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.clbc.2020.06.011_bib19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2020.06.011_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0027-5107(99)00012-3","article-title":"Estrogen, DNA damage and mutations","volume":"424","author":"Roy","year":"1999","journal-title":"Mutat Res"},{"key":"10.1016\/j.clbc.2020.06.011_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4137\/BCBCR.S39384","article-title":"Genomic changes in normal breast tissue in women at normal risk or at high risk for breast cancer","volume":"10","author":"Danforth","year":"2016","journal-title":"Breast Cancer (Auckl)"},{"key":"10.1016\/j.clbc.2020.06.011_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2020.06.011_bib23","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2006.02.016","article-title":"Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer","volume":"124","author":"Karin","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.clbc.2020.06.011_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.clbc.2020.06.011_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semcancer.2011.12.004","article-title":"Inflammation and immune surveillance in cancer","volume":"22","author":"Chow","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clbc.2020.06.011_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/npjbcancer.2016.7","article-title":"DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas","volume":"2","author":"Troester","year":"2016","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2020.06.011_bib27","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1242\/jcs.023820","article-title":"The extracellular matrix at a glance","volume":"123","author":"Frantz","year":"2010","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.clbc.2020.06.011_bib28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00418-008-0537-1","article-title":"Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging","volume":"130","author":"Ghajar","year":"2008","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.clbc.2020.06.011_bib29","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20140692","article-title":"Fibroblast heterogeneity in the cancer wound","volume":"211","author":"Ohlund","year":"2014","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clbc.2020.06.011_bib30","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.molmed.2017.02.009","article-title":"Adipocyte\u2013tumor cell metabolic crosstalk in breast cancer","volume":"23","author":"Hoy","year":"2017","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.clbc.2020.06.011_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lfs.2015.04.012","article-title":"Leptin, adipocytes and breast cancer: focus on inflammation and anti-tumor immunity","volume":"140","author":"Delort","year":"2015","journal-title":"Life Sci"},{"key":"10.1016\/j.clbc.2020.06.011_bib32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/obr.12377","article-title":"A\u00a0role for novel adipose tissue\u2013secreted factors in obesity-related carcinogenesis","volume":"17","author":"Cabia","year":"2016","journal-title":"Obes Rev"},{"key":"10.1016\/j.clbc.2020.06.011_bib33","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1111\/jcmm.12413","article-title":"Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer","volume":"18","author":"Madeddu","year":"2014","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.clbc.2020.06.011_bib34","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fimmu.2019.00348","article-title":"Immune tumor microenvironment in breast cancer and the participation of estrogen and its receptors in cancer physiopathology","volume":"10","author":"Segovia-Mendoza","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2020.06.011_bib35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cellimm.2015.01.018","article-title":"Estrogen receptors regulate innate immune cells and signaling pathways","volume":"294","author":"Kovats","year":"2015","journal-title":"Cell Immunol"},{"key":"10.1016\/j.clbc.2020.06.011_bib36","author":"Faas"},{"key":"10.1016\/j.clbc.2020.06.011_bib37","first-page":"635","article-title":"The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases","volume":"6","author":"Khan","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2020.06.011_bib38","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3389\/fimmu.2018.01332","article-title":"Glucocorticoids, sex hormones, and immunity","volume":"9","author":"Bereshchenko","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2020.06.011_bib39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/humupd\/dmi008","article-title":"Sex hormones and the immune response in humans","volume":"11","author":"Bouman","year":"2005","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.clbc.2020.06.011_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/2470289718801379","article-title":"Estrogen regulation of T-cell function and its impact on the tumor microenvironment","volume":"2","author":"Navarro","year":"2018","journal-title":"Gender Genome"},{"key":"10.1016\/j.clbc.2020.06.011_bib41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/modpathol.2015.158","article-title":"The immune microenvironment of breast ductal carcinoma in situ","volume":"29","author":"Thompson","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2020.06.011_bib42","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/cancers11091375","article-title":"The immune microenvironment of breast cancer progression","volume":"11","author":"Tower","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2020.06.011_bib43","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1158\/1078-0432.CCR-17-0743","article-title":"Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features","volume":"23","author":"Hendry","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2020.06.011_bib44","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13058-020-01267-w","article-title":"Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast","volume":"22","author":"Kim","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2020.06.011_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-019-05272-2","article-title":"Prognostic role of immune infiltrates in breast ductal carcinoma in situ","volume":"177","author":"Chen","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.06.011_bib46","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","article-title":"Immune escape in breast cancer during in situ to invasive carcinoma transition","volume":"7","author":"Gil Del Alcazar","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clbc.2020.06.011_bib47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/annonc\/mdw623","article-title":"The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast","volume":"28","author":"Pruneri","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","article-title":"Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast","volume":"161","author":"Campbell","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.06.011_bib49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/bcr1746","article-title":"Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression","volume":"9","author":"DeNardo","year":"2007","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2020.06.011_bib50","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00262-003-0409-4","article-title":"Naturally occurring B-cell responses to breast cancer","volume":"52","author":"Coronella-Wood","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clbc.2020.06.011_bib51","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/onc.2010.174","article-title":"Human FOXP3 and cancer","volume":"29","author":"Martin","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.clbc.2020.06.011_bib52","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib53","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/his.13217","article-title":"Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ","volume":"71","author":"Miligy","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.clbc.2020.06.011_bib54","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib55","first-page":"1231","article-title":"The role of lymphocytes and macrophages in human breast tumorigenesis: an immunohistochemical and morphometric study","volume":"22","author":"Ben-Hur","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2020.06.011_bib56","doi-asserted-by":"crossref","first-page":"E10409","DOI":"10.1073\/pnas.1713863114","article-title":"T\u00a0cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire","volume":"114","author":"Beausang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2020.06.011_bib57","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3892\/ijo.2016.3540","article-title":"Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy","volume":"49","author":"Park","year":"2016","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.canlet.2008.03.028","article-title":"Cancer related inflammation: the macrophage connection","volume":"267","author":"Sica","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clbc.2020.06.011_bib59","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.breast.2017.07.005","article-title":"Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: current state of the art","volume":"35","author":"Solinas","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2020.06.011_bib60","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10549-011-1647-3","article-title":"CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes","volume":"130","author":"Liu","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.06.011_bib61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib62","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41231-016-0005-1","article-title":"CD8+ tumor infiltrating lymphocytes strongly correlate with molecular subtype and clinico-pathological characteristics in breast cancer patients from Sudan","volume":"1","author":"Mohamed","year":"2016","journal-title":"Transl Med Commun"},{"key":"10.1016\/j.clbc.2020.06.011_bib63","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Sautes-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2020.06.011_bib64","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4049\/jimmunol.1701269","article-title":"Immune cell infiltration and tertiary lymphoid structures as determinants of antitumor immunity","volume":"200","author":"Engelhard","year":"2018","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clbc.2020.06.011_bib65","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1634\/theoncologist.2017-0029","article-title":"Distinct tertiary lymphoid structure associations and their prognostic relevance in HER2 positive and negative breast cancers","volume":"22","author":"Liu","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2020.06.011_bib66","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jclinpath-2015-203089","article-title":"Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer","volume":"69","author":"Lee","year":"2016","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.clbc.2020.06.011_bib67","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/0008-5472.CAN-11-0431","article-title":"Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer","volume":"71","author":"Martinet","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2020.06.011_bib68","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.4049\/jimmunol.1300872","article-title":"High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin beta-producing dendritic cells in human breast cancer","volume":"191","author":"Martinet","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clbc.2020.06.011_bib69","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00262-019-02407-8","article-title":"The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer","volume":"68","author":"Sofopoulos","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clbc.2020.06.011_bib70","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4143\/crt.2016.215","article-title":"Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer","volume":"49","author":"Song","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.06.011_bib71","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3389\/fimmu.2019.01398","article-title":"Tertiary lymphoid organs in cancer immunology: mechanisms and the new strategy for immunotherapy","volume":"10","author":"Lin","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2020.06.011_bib72","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0167-5699(95)80023-9","article-title":"High endothelial venules (HEVs): specialized endothelium for lymphocyte migration","volume":"16","author":"Girard","year":"1995","journal-title":"Immunol Today"},{"key":"10.1016\/j.clbc.2020.06.011_bib73","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130000","article-title":"Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients","volume":"4","author":"Egelston","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.clbc.2020.06.011_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aam6346","article-title":"Resident memory T cells in the skin mediate durable immunity to melanoma","volume":"2","author":"Malik","year":"2017","journal-title":"Sci Immunol"},{"key":"10.1016\/j.clbc.2020.06.011_bib75","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ni.3775","article-title":"Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer","volume":"18","author":"Ganesan","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clbc.2020.06.011_bib76","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","article-title":"Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis","volume":"24","author":"Savas","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clbc.2020.06.011_bib77","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/s13058-014-0488-5","article-title":"Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer","volume":"16","author":"Garc\u00eda-Mart\u00ednez","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2020.06.011_bib78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13058-018-0942-x","article-title":"Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population","volume":"20","author":"Schmidt","year":"2018","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2020.06.011_bib79","article-title":"Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling","volume":"12","author":"Park","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2020.06.011_bib80","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1158\/1535-7163.MCT-17-1005","article-title":"Tumor-infiltrating lymphocytes and PD-L1 expression in pre- and posttreatment breast cancers in the SWOG S0800 phase II neoadjuvant chemotherapy trial","volume":"17","author":"Pelekanou","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clbc.2020.06.011_bib81","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/1878-0261.12654","article-title":"Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor\u2013positive disease","volume":"14","author":"Zerdes","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib82","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib83","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2020.06.011_bib84","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2020.06.011_bib85","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2020.06.011_bib86","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.7147","article-title":"Current landscape of immunotherapy in breast cancer: a review","author":"Adams","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib87","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3389\/fendo.2017.00270","article-title":"Breast cancer vaccines: new insights","volume":"8","author":"Benedetti","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clbc.2020.06.011_bib88","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jvir.2017.07.018","article-title":"Immuno-oncology and its opportunities for interventional radiologists: immune checkpoint inhibition and potential synergies with interventional oncology procedures","volume":"28","author":"Hickey","year":"2017","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.clbc.2020.06.011_bib89","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition","volume":"15","author":"Hwang","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib90","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-019-0133-7","article-title":"If we build it they will come: targeting the immune response to breast cancer","volume":"5","author":"Gatti-Mays","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2020.06.011_bib91","series-title":"In: Proceedings of the San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, TX","article-title":"Recognition of autologous neoantigens by tumor infiltrating lymphocytes derived from breast cancer metastases","author":"Goff","year":"2017"},{"key":"10.1016\/j.clbc.2020.06.011_bib92","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.06.011_bib93","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1158\/1078-0432.CCR-16-1423","article-title":"Characterization of an immunogenic mutation in a patient with metastatic triple-negative breast cancer","volume":"23","author":"Assadipour","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2020.06.011_bib94","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/2326-6066.CIR-16-0364","article-title":"4-1BB\u2013enhanced expansion of CD8+ TIL from triple-negative breast cancer unveils mutation-specific CD8+ T cells","volume":"5","author":"Harao","year":"2017","journal-title":"Cancer Immunol Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920301555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920301555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:21:34Z","timestamp":1761513694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820920301555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1526820920301555"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2020.06.011","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2020.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}